ID: ALA1951346

Max Phase: Preclinical

Molecular Formula: C24H24N6O2

Molecular Weight: 428.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12

Standard InChI:  InChI=1S/C24H24N6O2/c1-14(2)28-23(31)17-5-4-6-19(11-17)30-24(32)29-18-9-7-16(8-10-18)21-20-15(3)12-25-22(20)27-13-26-21/h4-14H,1-3H3,(H,28,31)(H,25,26,27)(H2,29,30,32)

Standard InChI Key:  DFFVLCZIIWJVNO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 428.50

Molecular Weight (Monoisotopic): 428.1961

AlogP: 4.72

#Rotatable Bonds: 5

Polar Surface Area: 111.80

Molecular Species: NEUTRAL

HBA: 4

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.30

CX Basic pKa: 4.46

CX LogP: 4.06

CX LogD: 4.06

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.37

Np Likeness Score: -1.28

References

1. Song X, Li X, Ruiz CH, Yin Y, Feng Y, Kamenecka TM, Cameron MD..  (2012)  Imidazopyridines as selective CYP3A4 inhibitors.,  22  (4): [PMID:22264486] [10.1016/j.bmcl.2011.12.125]

2. Yin Y, Zheng K, Eid N, Howard S, Jeong JH, Yi F, Guo J, Park CM, Bibian M, Wu W, Hernandez P, Park H, Wu Y, Luo JL, LoGrasso PV, Feng Y..  (2015)  Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,  58  (4): [PMID:25621531] [10.1021/jm501680m]

3. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source

Source(1):

• Scientific Literature